NDC 0378-6950

Nevirapine

Nevirapine

Nevirapine is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Mylan Pharmaceuticals Inc.. The primary component is Nevirapine.

Product ID0378-6950_8c7d776f-cbd2-4de8-85b9-efe2cf74a71c
NDC0378-6950
Product TypeHuman Prescription Drug
Proprietary NameNevirapine
Generic NameNevirapine
Dosage FormTablet, Extended Release
Route of AdministrationORAL
Marketing Start Date2015-11-09
Marketing End Date2019-10-31
Marketing CategoryANDA / ANDA
Application NumberANDA206271
Labeler NameMylan Pharmaceuticals Inc.
Substance NameNEVIRAPINE
Active Ingredient Strength100 mg/1
Pharm ClassesHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [EXT],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA]
NDC Exclude FlagN

Packaging

NDC 0378-6950-77

90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-6950-77)
Marketing Start Date2015-11-09
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0378-6950-05 [00378695005]

Nevirapine TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA206271
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2015-11-09
Marketing End Date2018-01-15

NDC 0378-6950-77 [00378695077]

Nevirapine TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA206271
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2015-11-09
Marketing End Date2019-10-31

NDC 0378-6950-93 [00378695093]

Nevirapine TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA206271
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2015-11-09
Marketing End Date2018-01-15

Drug Details

Pharmacological Class

  • Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
  • Non-Nucleoside Analog [EXT]
  • Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
  • Cytochrome P450 3A Inducers [MoA]
  • Cytochrome P450 2B6 Inducers [MoA]

NDC Crossover Matching brand name "Nevirapine" or generic name "Nevirapine"

NDCBrand NameGeneric Name
0378-4050Nevirapinenevirapine
0378-4890Nevirapinenevirapine
0378-6950Nevirapinenevirapine
0781-5893NevirapineNevirapine
31722-505NevirapineNevirapine
33342-004NevirapineNevirapine
33342-238NEVIRAPINENEVIRAPINE
42571-131NEVIRAPINENEVIRAPINE
51991-331NevirapineNEVIRAPINE
53104-0166nevirapinenevirapine
53808-0680Nevirapinenevirapine
53808-1069nevirapinenevirapine
61442-470NevirapineNevirapine
64380-709NevirapineNevirapine
65162-209NevirapineNevirapine
69097-403NEVIRAPINENEVIRAPINE
69097-233nevirapinenevirapine
65862-057NevirapineNevirapine
65862-027NevirapineNevirapine
65862-932NEVIRAPINENEVIRAPINE
65862-933NEVIRAPINENEVIRAPINE
47781-317Nevirapine Extended Releasenevirapine
0597-0046Viramunenevirapine
0597-0047Viramunenevirapine
0597-0123Viramunenevirapine
53808-0808Viramunenevirapine
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.